


Please type a plus sign (+) inside this box → ☐

(Modified) PTO/SB/21 (6-98)

Approved for use through 09/30/2000. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



# TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

<b>TRANSMITTAL FORM</b> (to be used for all correspondence after initial filing)	Application Number	09/601,971	
	Filing Date	March 29, 1999	
	First Named Inventor	RADEMACHER, Thomas	
	Group Art Unit	1644	
	Examiner Name	Amy M. Decloux	
Total Number of Pages in This Submission	5	Attorney Docket Number	1012-010000US

## ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Small Entity Statement <input type="checkbox"/> Request for Refund	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Additional Enclosure(s) (please identify below): Request for corrected filing receipt; Marked up copy of Official Filing Receipt; receipt acknowledgment postcard
--	---	--

## Authorization to Charge Deposit Account

Please charge Deposit Account No. 50-0893 for any additional fees associated with this paper or during the pendency of this application, including any extensions of time for consideration of the documents enclosed.

Remarks

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Irene Pleasure, Reg. No. 45,506, Quine Intellectual Property Law Group, P.C.
Signature	<i>Irene J. Pleasure</i>
Date	October 9, 2002

RECEIVED

NOV 08 2002

## CERTIFICATE OF MAILING

TECH CENTER 1600/2900

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: October 9, 2002

Typed or printed name	Amelia Groth
Signature	<i>Amelia Groth</i>
Date	October 9, 2002



I hereby certify that this correspondence is being deposited with the United States Postal Service first class mail in an envelope addressed to:  
Assistant Commissioner for Patents, Washington, D.C. 20231,  
on October 9, 2002

Attorney Docket No. 1012-010000US

By Amelia Groth  
QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

RADEMACHER, Thomas William, et al.

Application No.: 09/601,971

Filed: March 29, 1999

For: **IPG ANTAGONISTS FOR THE TREATMENT  
OF CONDITIONS INVOLVING MAST CELLS,  
BASOPHILS AND EOSINOPHILS**

Examiner: Amy M. Decloux

Art Unit: 1644

**REQUEST FOR CORRECTED FILING  
RECEIPT**

Assistant Commissioner for Patents  
Office of Initial Patent Examination  
Customer Service Center  
Washington, D.C. 20231

Sir:

Attached is a copy of the official Filing Receipt received from the Patent and Trademark Office in the above-noted application for which issuance of a corrected filing receipt is respectfully requested.

There is an error in that the title should read as follows:

**IPG antagonists for the treatment of conditions involving mast cells, basophils and eosinophils**

**RECEIVED**

NOV 08 2002

TECH CENTER 1600/2900


RADEMACHER, Thomas William, et al.

Application No.: 09/601,971

Page 2

It is believed that no fee is due. If a fee is due, please charge Deposit Account  
No. 50-0893.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Irene Pleasure", is written over the typed name.

Irene Pleasure, J.D., Ph.D.  
Reg. No. 45,506

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.

P.O. BOX 458

Alameda, CA 94501

(510) 337-7871

Fax (510) 337-7877



Commissioner for Patents  
Washington, DC 20231  
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/601,971	08/09/2000	1644	550	1012-100US	4	11	3

CONFIRMATION NO. 5898

Jonathan Alan Quine  
Law Offices Of Jonathan Alan Quine  
PO Box 458  
Alameda, CA 94501

**RECEIVED**

OCT 01 2002

CORRECTED FILING RECEIPT



\*OC000000008864192\*

Quine Intellectual Property Law Group, P.C.

Date Mailed: 09/26/2002

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

**Applicant(s)**

Thomas William Rademacher, Oxford, UNITED KINGDOM;  
Helen Whitby, London, UNITED KINGDOM;

**Domestic Priority data as claimed by applicant**

This application is a 371 of PCT/GB99/00981 03/29/2000

**Foreign Applications**

UNITED KINGDOM 9806645.9 03/27/1998

If Required, Foreign Filing License Granted 09/07/2000

Projected Publication Date: None, application is not eligible for pre-grant publication

Non-Publication Request: No

Early Publication Request: No

**Title**

**ANTAGONISTS**  
IPG ANTAGONISTS FOR THE TREATMENT OF CONDITIONS INVOLVING MAST CELLS,  
BASOPHILS AND EOSINOPHILS

**RECEIVED**

NOV 08 2002

TECH CENTER 1600/2900

Preliminary Class

424

---

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).